Comparative cardiovascular effects of GLP-1 agonists using real-world data

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Limited real-world data exist on the cardiovascular protective effects of glucagon-like peptide-1 (GLP-1) agonists in adults with type 2 diabetes (T2D) early in treatment.
• GLP-1 agonists are increasingly used for T2D management, making understanding their cardiovascular safety profile crucial.

Purpose of the Study:

• To evaluate and compare cardiovascular disease (CVD) event rates among adults with T2D initiating exenatide extended-release (E-ER), exenatide immediate-release (E-IR), or liraglutide.
• To assess the real-world effectiveness of different GLP-1 agonists in preventing major adverse cardiovascular events (MACE).

Main Methods:

• Retrospective cohort study using administrative claims data from 2011-2015.
• Included T2D adults previously treated only with metformin, comparing CVD event rates after initiating E-ER, E-IR, or liraglutide.
• Primary outcome was time to first major adverse CVD event; Cox proportional hazards regression was used for analysis.

Main Results:

• Neither E-ER nor E-IR was associated with a significantly different risk of composite major CVD events compared to liraglutide (HRs: 1.33 [0.73-2.39] for E-ER, 1.30 [0.81-2.09] for E-IR).
• No significant associations were observed for individual CVD components, though the hazard ratio for ischaemic events with E-IR versus liraglutide was 1.85 (0.97-3.53).
• Results remained consistent after adjusting for time-varying exposure to other antidiabetic and CVD medications.

Conclusions:

• Initiating exenatide (immediate or extended-release) rather than liraglutide was not associated with significant differences in CVD risk in this observational study.
• This real-world evidence suggests comparable cardiovascular safety profiles for these GLP-1 agonists when initiated as first-line therapy beyond metformin.